West Pharmaceutical Services (WST) Cost of Revenue (2009 - 2026)

West Pharmaceutical Services' Cost of Revenue history runs 18 years deep, the most recent figure standing at $548.5 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 17.68% year-over-year to $548.5 million; the TTM figure through Mar 2026 stood at $2.1 billion (up 8.28% YoY), while the FY2025 annual figure was $2.0 billion, up 3.98% from the prior year.
• Cost of Revenue came in at $548.5 million for Q1 2026 at West Pharmaceutical Services, up from $501.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $548.5 million in Q1 2026 to a low of $418.9 million in Q3 2022.
• A 5-year average of $469.7 million and a median of $465.2 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue advanced 0.14% in 2022 and increased 17.68% in 2026, its largest moves.
• West Pharmaceutical Services' Cost of Revenue stood at $446.6 million in 2022, then rose by 1.61% to $453.8 million in 2023, then climbed by 4.72% to $475.2 million in 2024, then advanced by 5.45% to $501.1 million in 2025, then increased by 9.46% to $548.5 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $548.5 million, $501.1 million, and $510.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison